Retraction note: Volume replacement in critically ill intensive-care patients: No classic review (Anaesthesist, (1998), 10.1007/s001010050625);Retraction Note: Volumenersatz beim schwerkranken Intensivpatienten: Keine klassische Übersicht (Anaesthesist, (1998), 10.1007/s001010050625);Volume replacement in critically ill intensive-care patients. No classic review;Volumenersatz beim schwerkranken intensivpatienten. Keine klassiche ubersicht

Anaesthesist

Volumn 47, Issue 9, 1998, Pages 778-785

  Boldt, J ^a  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

Author keywords

Albumin; Coagulation; Critical ill; Dextrane; Gelatin; Hydroxyethyl starch; Macrocirculation; Microcirculation; Organ function; Side effects; Volume replacement

Indexed keywords

ALBUMIN; DEXTRAN; GELATIN; HETASTARCH;

ARTICLE; BLOOD CLOTTING; COLLOID; CRITICAL ILLNESS; FLUID THERAPY; HEMOSTASIS; HUMAN; HYPOVOLEMIA; IMMUNE SYSTEM; KIDNEY FUNCTION; LIVER FUNCTION; MICROCIRCULATION; ORGAN BLOOD FLOW; RESUSCITATION;

EID: 0031661542     PISSN: 00032417     EISSN: 1432055X     Source Type: Journal    
DOI: 10.1007/s00101-021-01071-x     Document Type: Erratum

References (53)

1. Adams HA, Michaelis R, Hempelmann G (1993) Die Indikation zum Einsatz von Humanalbumin in Anästhesie und Intensivmedizin. Anästhesiol Intensivmed Notfallmed Schmerzther 28:66-74
2. Adams HA, Piepenbrock S, Hempelmann G (1998) Volumenersatzmittel - Pharmakologie und klinischer Einsatz. Anästhesiol Intensivmed Notfallmed Schmerzther 33:2-17
3. Beards SC, Watt T, Edwards JD, Nightingale P, Farragher EB (1994) Comparison of the hemodynamic and oxygen transport responses to modified fluid gelatin and hetastarch in critically ill patients: a prospective, randomized trial. Crit Care Med 22:600-605
4. Boldt J, Kling D, Zickmann B, Jacobi M, Bormann B v, Dapper F, Hempelmann G (1990) Acute plasmapheresis during cardiac surgery: volume replacement by crystalloids versus colloids. J Cardiothorac Anesth 4:564-570
5. Boldt J, Zickmann B, Benson M, Ballesteros M, Stertmann F, Hempelmann G (1992) Influence of 5 different priming on platelet function in patients undergoing cardiac surgery. Anesth Analg 74:219-225
6. Boldt J, Knothe Ch, Zickmann B, Andres P, Dapper F, Hempelmann G (1993) Influence of different intravascular volume therapy on platelet function in patients undergoing cardiopulmonary bypass. Anesth Analg 76:1185-1190
7. Boldt J, Heesen M, Welters I, Padberg W, Hempelmann G (1995) Does the type of volume therapy influence endothelial-related coagulation in the critically ill? Br J Anaesth 75:740-746
8. Boldt J, Zickmann B, Rapin J, Hammermann H, Dapper F, Hempelmann G (1994) Influence of volume replacement with different HES-solutions on microcirculatory blood flow in cardiac surgery. Acta Anaesthesiol Scand 8:432-438
9. Boldt J, Müller M, Heesen M, Martin K, Hempelmann G (1996) Influence of different volume therapies and pentoxifylline infusion on circulating soluble adhesion molecules in critically ill patients. Crit Care Med 24:385-391
10. Boldt J, Müller M, Mentges D, Papsdorf M, Hempelmann G (1996) Influence of different volume therapy regime on regulators of circulation in the critically ill. Br J Anaesth 77:480-487
11. Boldt J, Müller M, Mentges D, Papsdorf M, Hempelmann G (1998) Volume therapy in the critically ill: is there a difference? Intensive Care Med 24:28-36
12. Boldt J, Lenz M, Kumle B, Papsdorf M (1998) Volume replacement strategies on intensive care units: results from a postal survey. Intensive Care Med 24:147-151
13. Chaudry IH, Ayala A (1993) Immune consequences of hypovolemic shock and resuscitation. Curr Opinion Anesth 6:385-392
14. Collis RE, Collins PW, Gutteridge CN, Faul A, Newland AC, Williams DM, Webb AR (1994) The effect of hydroxyethyl starch and other plasma volume substitutes on endothelial cell activation; an in vitro study. Intensive Care Med 20:37-41
15. Davidson I (1989) Fluid resuscitation of shock: current controversies. Crit Care Med 17:1078-1080
16. Dehne MG, Mühling J, Sablotzki A, Papke G, Kuntzsch U, Hempelmann G (1997) Einfluß von Hydroxyethylstärke auf die Nierenfunktion bei operativen Intensivpatienten. Intensivmed Intensivmed Notfallmed Schmerzther 32:348-354
17. Dietrich G, Orth D, Haupt W, Kretschmer V (1990) Primary hemostasis in hemodilution - infusion solutions. Infusionsther 17:214-216
18. Edwards JD, Nightingale P, Wilkins RG, Faragher EB (1988) Hemodynamic and oxygen transport response to modified fluid gelatin in the critically ill patients. Crit Care Med 17:996-998
19. Edwards JD (1994) A new debate: colloid versus colloid? In: Vincent JL (ed) Yearbook of Intensive Care and Emergency Medicine. Springer, Berlin Heidelberg New York, pp 152-164
20. Ehrly AM, Hörl WH, Schmitz JE, Staedt U (1993) Stellungnahme zu der Bekanntgabe der Arzneimittelkommisson der Deutsche Ärzteschaft: Nochmals:"Vorsicht bei Hämodilutionstherapie mit Hydroxyethylstärke (HES)". Dtsch Ärztebl 90:B-2454
21. Emmerson TE (1989) Unique features of albumin: a brief review. Crit Care Med 17:690-694
22. Förster H (1998) Grundlagen zur Anwendung von Hydroxyethylstärke. J Anästh Intensivbehandlung [Suppl] 2:551-554
23. Gahr R (1981) Aktuelle Volumentherapie mit kolloidalen Lösungen. Wissenschaftliche Informationen Anästhesie, Fresenius-Stiftung 2:1-18
24. Gall H, Kaufmann R, Ehr M v, Schumann K, Sterry W (1993) Persistierender Pruritus nach Hydroxyäthylstärke-Infusionen. Hautarzt 44:713-716
25. Gressier M, Lehot JJ, George M, Dupraz F, Bastien O, Estanove S (1994) Albumin use and abuse after cardiac surgery. J Cardiothorac Vasc Anesth [Suppl 3] 8:82
26. Kapila A, Waldman CS, Uncles DR, Addy EV (1995) Survey of colloid usage in British intensive care units. Clin Intensive Care 6:A201
27. Kirkpatrik CJ, Klosterhalfen B, Hauptmann S (1992) The role of the endothelium in multiple organ failure. In: Vincent JL (ed) Yearbook of Intensive Care and Emergency Medicine. Springer, Berlin Heidelberg New York, pp 14-24
28. Lackner FX, Graninger W, Illias W, Panzer S, Schulz E (1990) Präoperative Eigenblutspende, der Einfluß von Hydroxyäthylstärke auf Rekuloendothelialsystem und Opsonine. Infusionsther 17:276-279
29. Laubenthal H (1989) Einsatzstrategien für Albumin. Beitr Infusionsther 24:102-111
30. Laxenaire M, Charpentier C, Feldman L (1994) Reactions anaphylactoides aux subitutes colloidaux du plasma: incidence, facteurs de risque, mecanismes. Ann Fr Anest Reanim 13:301-310
31. Lewis DH (1988) The effects of multiple organ failure on the regulation of the circulation with special reference to the microcirculation. In: Manabe H, Zweifach BW, Messmer K (eds) Microcirculation in circulatory disorders. Springer, Tokyo Berlin Heidelberg New York, pp 103-108
32. Metze D, Reimann S, Szepfalusi Z, Bohle B, Kraft D, Luger TA (1997) Persistent pruritus after hydroxyethyl starch infusion therapy: a result of long-term storage in cutaneous nerves. Br J Dermatol 136:553-559
33. Niemer M, Nemes C, Lundsgaard-Hansen P, Blauhut B (1992) Datenbuch Intensivmedizin, 3. Aufl. Fischer, Stuttgart Jena New York, p 942
34. Parth E, Jurecka W, Szepfalusi Z, Schimetta W, Gebhardt W, Scheiner O, Graft D (1992) Histological and immunohistochemical investigations of hydroxyethyl starch deposite in rat tissues. Eur Surg Res 24:13-27
35. Prough DS, Johnston WE (1989) Fluid restoration in septic shock: no solution yet. Anesth Analg 69:699-704
36. Ring J, Messmer K (1977) Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 11:466-469
37. Sakka SG, Reinhart K (1996) Volumentherapie im septischen Schock. Intensiv- und Notfallbehandlung 21:73-79
38. Schmand JF, Ayala A, Morison MH, Chaudry IH (1995) Effects of hydroxyethyl starch after trauma-hemorrhagic shock: restoration of macrophage integrity and prevention of increased circulating interleukin-6 levels. Crit Care Med 23:806-814
39. Schneeberger R, Albegger K, Oberascher G, Miller K (1990) Juckreiz - eine Nebenwirkung von Hydroxyäthylstärke (HES)? HNO 38:298-303
40. Sibbald WJ (1994) Fluid therapy in sepsis. In: Reinhard K, Eyrich K, Sprung C (eds) Sepsis - current perspectives in pathophysiology and therapy. Update in Intensive Care and Emergency Medicine, vol 18. Springer, Berlin Heidelberg New York, pp266-273
41. Sirtl C, Hübner G, Jesch F (1988) Zur Speicherung hoch- und mittelmolekularer Hydroxyäthylstärke (HÄS) im menschlichen Gewebe. Beitr Anästh Intensivmed 26:74-97
42. Spittal MJ, Findlay GP (1995) The seven year itch. Anaesthesia 50:913-914
43. Strauss RG (1981) Review of the effects of hydroxyethyl starch on the blood coagulation system. Transfusion 21:299-309
44. Stockwell MA, Scott A, Day A, Riley B, Soni N (1992) Colloid solutions in the critically ill. Anaesthesia 47:3-9
45. Thurner F (1994) Vergleich vier verschiedener Plasmaexpander bezüglich plasmatischer und thrombozytärer Gerinnungsstörung. Intensiv-Notfallbehandlung 19:8-13
46. Treib J, Haass A, Pindur G, Grauer MT, Wenzel E, Schimrigk K (1996) All medium starches are not the same: influence of hydroxyethyl substitution of hydroxyethhyl starch on plasma volume, hemorrheologic conditions, and coagulation. Transfusion 36:450-455
47. Treib J, Haass A, Pindur G (1997) Coagulation disorders caused by hydroxyethyl starch. Thromb Haemost 78:974-983
48. Treib J, Haass A, Pindur G, Wenzel E, Schimrigk K (1997) Blutungskomplikationen durch Hydroxyethylstärke sind vermeidbar. Dtsch Ärztebl 94:B1896-B1900
49. Vincent JL (1991) The colloid-crystalloid controversy. Klin Wochenschr [Suppl XXVI] 69:104-111
50. Warren BB, Durieux ME (1996) Hydroxyethylstarch: safe or not? Anesth Analg 84:206-212
51. Vogt NH, Bothner U, Lerch G, Lindner KH, Georgieff M (1996) Large-dose administration of 6% hydroxyethyl starch 200/0.5 for total hip arthroplasty: plasma homeostasis, hemostasis, and renal function compared to use of 5% human albumin. Anesth Analg 83:262-268
52. Weidhase R, Faude K, Weidhase R (1998) Hydroxyethylstärke - ein Zwischenbericht. Anaesth Reanimat 23:4-14
53. Zikria BA, Subbarao C, Oz MC, Poilkis SJ, Sachdev R, Chauhan P, Freeman HP, King TC (1990) Hydroxyethyl starch macromolecules reduce myocardial reperfusion injury. Arch Surg 125:930-934